Disc Medicine Inc
For the period ended Sep 30, 2024. Filed Nov 12, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 12, 2024
IRON$84.64+4.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| Nine Months EndedSeptember 30, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities | ||
| Net loss | $(79,900) | $(52,850) |
| Adjustments to reconcile net loss to net cash used in operations: | ||
| Depreciation and amortization | 147 | 75 |
| Stock-based compensation | 12,481 | 3,603 |
| Amortization/accretion of investment securities | (3,092) | — |
| Change in fair value of contingent value right liability | — | 1,500 |
| Noncash lease expense | 324 | 180 |
| Other non-cash items | (42) | — |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (509) | 341 |
| Accounts payable | (9,076) | (7,710) |
| Accrued external research and development expenses | 14,346 | 132 |
| Other accrued expenses | (647) | (849) |
| Operating lease liabilities | (385) | (88) |
| Net cash used in operating activities | (66,353) | (55,666) |
| Cash flows from investing activities | ||
| Purchases of property and equipment | (56) | (86) |
| Purchases of marketable securities | (313,850) | — |
| Maturities of marketable securities | 23,000 | — |
| Net cash used in investing activities | (290,906) | (86) |
| Cash flows from financing activities | ||
| Proceeds from sale of common stock in offerings, net of issuance costs paid | 172,512 | 192,126 |
| Proceeds from sale of pre-funded warrants in offerings, net of issuance costs paid | — | 37,579 |
| Proceeds from sale of common stock in at-the-market offerings, net of issuance costs paid | 14,790 | — |
| Proceeds from stock option exercises | 1,774 | 1,916 |
| Contributions from employee stock purchase plan | 441 | — |
| Net cash provided by financing activities | 189,517 | 231,621 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | (167,742) | 175,869 |
| Cash, cash equivalents and restricted cash, beginning of period | 360,616 | 194,788 |
| Cash, cash equivalents and restricted cash, end of period | $192,874 | $370,657 |
| Supplemental cash flow information | ||
| Cash paid for income taxes | $37 | $78 |
| Supplemental disclosure of non-cash activities | ||
| Right-of-use assets obtained in exchange for new operating lease liabilities | $— | $1,106 |
| Net increase (decrease) in right-of-use assets related to lease modifications and reassessment events | $72 | $(422) |
| Net increase (decrease) in operating lease liabilities related to lease modifications and reassessment events | $72 | $(392) |
| Deferred issuance costs on sale of common stock and pre-funded warrants in offerings included in accounts payable and accrued expenses | $— | $215 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.